Barclays lowered the firm’s price target on Syneos Health to $37 from $45 and keeps an Underweight rating on the shares. The macro environment "continues to dominate the conversation" heading into the Q1 results for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm expects results in line with the "relatively light" Q1 guides with "no risk clearings yet." It still believes in the recovery and expects some relief in Q2 for a better second half of the year setup.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Names Jeanine O’Kane as Communications President
- Syneos Health launches Medical Affairs Digital Amplifier
- Syneos Health Launches Medical Affairs Digital Amplifier
- Syneos Health and KX team on predictive analytics, AI and ML
- Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development